trending Market Intelligence /marketintelligence/en/news-insights/trending/ttM2jWNztGaxUQrccJk66A2 content esgSubNav
In This List

Medicure files abbreviated application with US FDA for cardiovascular drug

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Medicure files abbreviated application with US FDA for cardiovascular drug

Medicure Inc. filed an abbreviated new drug application to the U.S. FDA for a cardiovascular generic drug, developed as a collaboration between Medicure unit Medicure International Inc. and Apicore US LLC.

The filing was the result of a project focused on the development of an intravenous drug product for an acute cardiovascular indication.

The company and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.

Medicure currently owns majority interest in Apicore, with an option to acquire the remaining issued shares of Apicore until July 2017.